NCT03162055
Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Phase: Phase 3
Role: Collaborator
Start: May 25, 2017
Completion: May 4, 2018